Current Announcements

Wednesday, 06 June 2007

Help could be close at hand for those suffering with advanced melanoma

View a recent TV newsitem about a new melanoma test from Pacific Edge

Scientists say the disease is hard to treat, but the melanoma test they're developing would make it easier to find the most effective treatment.

The test, being developed in a collaboration with Dunedin company Pacific Edge Biotechnology, has passed the first development phase with flying colours.

Wednesday, 6 June 2007

Research Agreement with the Ludwig Institute and Presentation to American Society of Clinical Oncology Announced

Today Pacific Edge Biotechnology issued a press release announcing signing of a collaborative research agreement with the Ludwig Institute for Cancer Research. Promising early results for an aggressive melanoma test will be presented at the American Society of Clinical Oncology annual meeting.

Friday, 4 May 2007

PEBL CEO on NZ National Radio Morning Report

Pacific Edge Biotechnology Ltd CEO David Darling gave his views on the potential benefits for biotechnology companies of possible tax incentives for research.

The original Radio NZ link is here and it has been archived here. Mr Darling's comments are at 1 min 56 seconds into the item.

Wednesday, 11 April 2007

Push For More Technology Companies In New Zealand

On 11 Apr 2007 Channel 9 Dunedin did a news story on the visit of Finance Minister Michael Cullen to Pacific Edge Biotechnology

Finance Minister Michael Cullen says new tax incentives in the upcoming budget will encourage technology businesses to stay based in New Zealand. Cullen visited Pacific Edge Biotechnology in Dunedin today to find out how companies like them are coping in the New Zealand market.

December 2006

PEB Invited to take part in a discussion panel at the Burrill & Co Personalized Medicine Meeting

Dave Darling, CEO of Pacific Edge Biotechnology, was recently invited to be part of a discussion panel at The 2nd Annual Personalized Medicine Meeting- From Prediction to Prevention

A special Webcast, sponsored by Luminex, provides an overview of the two-day Burrill Personalized Medicine meeting,which encompassed detailed discussions on the whole spectrum of personalized medicine - from prediction to prevention - providing attendees with a detailed "window" into the emerging personalized medicine world. This meeting brought together over 300 delegates drawn from science and health care, along with payers and regulators, as well as the financial community and pharma and biotech CEOs. The complete webcast of all the meetings presentations is also available, at an additional charge from Burrill.

Participants:
G. Steven Burrill, CEO, Burrill & Company
Edward Abrahams, Executive Director, The Personalized Medicine Coalition (PMC)
Patrick J. Balthrop, President and CEO, Luminex Corporation

October 2006

How can a bunch of scientists from a little-known university in a little-known country be leading in the battle with cancer?

Read the Otago Daily Times article about responses to a presentation by CEO David Darling here

19 September 2006

Pacific Edge Biotechnology Licenses Multigene Colorectal Cancer Diagnostics for European Market

David Darling, Chief Executive Officer

Pacific Edge has signed an European exclusive license with Signature Diagnostics AG on a multi-gene assay for predicting progression of patients with early stag e colorectal cancer. Upon validation this assay will allow the identification of patients at high risk of cancer metastasis so that additional treatment can be offered to prevent or delay recurrence.

Signature Diagnostics is a German diagnostic company specialized in prognostic and predictive multimarker diagnostics in colorectal cancer. Under the terms and conditions of the license agreement Signature Diagnostics will carry out the retrospective validation, commercial development, registration as well as the marke ting and sales of the assay in Europe. Pacific Edge will receive a license fee as well as milestone and royalties payments dependent on the development stage of the product. Financial details are not released. Pacific Edge will also embark on a collaborative research program with Signature to develop further colorectal cancer assays.

Colorectal cancer has a large impact worldwide with over 1.1 million new cases annually. The incidence is particularly high in Australasia, Europe and North America. This year over 530,000 people, globally, are anticipated to die from the disease.

Pacific Edge has a number of programs aimed at developing novel tools and methods for the early detection and management of cancers. Its most advanced programs are in colorectal cancer, bladder cancer and gastric cancer.